from Reuters: Health News https://reut.rs/2WYT0q3
Gilead misses key goal in NASH liver disease trial, shares sink
Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company's shares down 4.6 percent in after-hours trading.
from Reuters: Health News https://reut.rs/2WYT0q3
from Reuters: Health News https://reut.rs/2WYT0q3
Subscribe to:
Post Comments (Atom)
-
The German cabinet will hold a secret session on Wednesday to discuss safeguard measures regarding the possible participation of China's...
-
Stocks poised for another day of gains Equity markets look to add to the gains from the prior session as investor concerns about the fu...
-
By LIAM STACK from NYT Magazine https://ift.tt/2FNPp6k
No comments:
Post a Comment